Chloroarenes

Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day

Retrieved on:

Wednesday, June 23, 2021

Drugs, Organic compounds, Bristol-Myers Squibb, Chloroarenes, Clopidogrel, Hepatotoxins, Prodrugs, Sanofi, Chemical compounds

Presentations will highlight Jounces productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064.

Key Points:

Presentations will highlight Jounces productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064.
More specifically, we will discuss the monotherapy dose escalation status of our INNATE trial of JTX-8064.
Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.
Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

Retrieved on:

Tuesday, June 22, 2021

Tyrosine kinase receptors, Lung cancer, Organic compounds, Quinazolines, Chemical compounds, Non-small-cell lung carcinoma, Tyrosine kinase, C-Met, Branches of biology, Tyrosine kinase inhibitors, Chloroarenes, Icotinib

Approximately 2-3% of newly diagnosed NSCLC patients have MET exon skipping 14 alterations, a specific genetic mutation.

Key Points:

Approximately 2-3% of newly diagnosed NSCLC patients have MET exon skipping 14 alterations, a specific genetic mutation.
Savolitinib is an oral, potent and selective MET TKI that has demonstrated clinical activity in advanced solid tumors.
It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations).
HUTCHMED is responsible for the manufacturing and supply of savolitinib, and AstraZeneca is responsible for its commercialization in China and worldwide.

FDA Approves a Nasal Antihistamine for Nonprescription Use

Retrieved on:

Thursday, June 17, 2021

Medicine, Medical specialties, Clinical medicine, Allergology, Chloroarenes, Dosage forms, Azelastine, Lactams, Nasal spray, Rhinitis, Food and Drug Administration, Bayer

SILVER SPRING, Md., June 17, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch.

Key Points:

SILVER SPRING, Md., June 17, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch.
The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitiscommonly known as allergiesfor adults and children six years of age and older.
"Today's approval provides individuals an option for a safe and effective nasal antihistamine without requiring the assistance of a healthcare provider."
The FDA granted the approval of nonprescription Astepro to Bayer Healthcare LLC.

Montrose Environmental Group Acquires Vista Analytical Laboratory

Retrieved on:

Thursday, June 17, 2021

Montrose Environmental Group, Inc. (the Company or Montrose) (NYSE: MEG) today announced the acquisition of Vista Analytical Laboratory (Vista), a premier environmental laboratory for the testing and analysis of polyfluoroalkyl substances (PFAS), dioxins and other persistent organic pollutants.

Key Points:

Montrose Environmental Group, Inc. (the Company or Montrose) (NYSE: MEG) today announced the acquisition of Vista Analytical Laboratory (Vista), a premier environmental laboratory for the testing and analysis of polyfluoroalkyl substances (PFAS), dioxins and other persistent organic pollutants.
Vista holds 21 state accreditations and is certified by the California Environmental Laboratory Accreditation Program to perform PFAS analysis for all 31 PFAS compounds currently being monitored in California.
Vista strengthens our ability to provide clients with an end-to-end environmental solution, from advisory services and testing to engineering and remediation, particularly given our clients focus on PFAS, said Vijay Manthripragada, Chief Executive Officer of Montrose Environmental Group.
Vista Analytical is a premier environmental laboratory for the determination of dioxins and furans, PCBs, PFAS, PAHs, PBDEs, PCNs and other semi-volatile organic contaminants.

Irrimax Receives FDA Clearance for Irrisept® as an Antimicrobial Wound Lavage for US Market

Retrieved on:

Thursday, June 17, 2021

Clinical medicine, Medicine, Applied sciences, Therapeutic irrigation, Chloroarenes, Chlorhexidine, Antimicrobial, Irrigation

LAWRENCEVILLE, Ga., June 17, 2021 /PRNewswire/ --- Irrimax Corporation, manufacturer of Irrisept, announces new clearance from the U.S. Food and Drug Administration (FDA), making Irrisept the only self-contained irrigation system for antimicrobial wound lavage in the U.S. market.

Key Points:

LAWRENCEVILLE, Ga., June 17, 2021 /PRNewswire/ --- Irrimax Corporation, manufacturer of Irrisept, announces new clearance from the U.S. Food and Drug Administration (FDA), making Irrisept the only self-contained irrigation system for antimicrobial wound lavage in the U.S. market.
As a result of the new clearance, Irrimax announces a new product name "Irrisept Antimicrobial Wound Lavage".The indications for use now include the mechanical cleansing and removal of microorganisms.
"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said MarkAlvarez, CEO of Irrimax.
Irrisept Antimicrobial Wound Lavage is offered as a single-use, manual, self-contained irrigation devicecomprised of 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, USP.

Ketamine One Highlights Psychedelic Research and Announces New Clinical Trial

Retrieved on:

Thursday, June 17, 2021

Psychoactive drugs, Drugs, Health sciences, Drug discovery, Antidepressants, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Ketamine, Psychedelic therapy, Clinical trial, Clinical

KGK is rapidly being integrated into Ketamine Ones mental health platform, accelerating the ability to foster value creation through the Companys clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work.

Key Points:

KGK is rapidly being integrated into Ketamine Ones mental health platform, accelerating the ability to foster value creation through the Companys clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work.
Being at the forefront of psychedelics research strongly positions Ketamine One and KGK to generate defendable intellectual property and secure first mover advantages.
Further, the Company is pleased to report that KGK has recently been awarded a new clinical trial contract, a research project and has also completed two studies.
Developing a network of vertically-integrated clinics within Ketamine One for the conduct of psychedelic clinical trials.

Ketamine One Closes Previously Announced Acquisition of Integrated Rehab and Performance

Retrieved on:

Tuesday, June 15, 2021

Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Antidepressants, Chloroarenes, Nicotinic antagonists, General anesthetics, Ketamine

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (Ketamine One or the Company) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has closed its previously announced acquisition (the Acquisition) of Integrated Rehab and Performance Ltd. (IRP).

Key Points:

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (Ketamine One or the Company) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has closed its previously announced acquisition (the Acquisition) of Integrated Rehab and Performance Ltd. (IRP).
As consideration for the Transaction, Ketamine One issued 602,410 common shares of the Company (the Consideration Shares) at a price per common share of $1.66.
Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receiving Iomab-B Presented at 2021 SNMMI Virtual Conference

Retrieved on:

Tuesday, June 15, 2021

Branches of biology, Medical specialties, Chemical compounds, Hematology, Anatomical pathology, Benzamides, Chloroarenes, Sulfonamides, Venetoclax, Bcl-2, Lymphoma, Leukemia

Via the monoclonal antibody apamistamab, Iomab-B targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, immune cells and stem cells.

Key Points:

Via the monoclonal antibody apamistamab, Iomab-B targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, immune cells and stem cells.
A bone marrow transplant is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders.
The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.
Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.

Leading Psychedelic Wellness Company Delic Signs Definitive Agreement to Acquire Ketamine Infusion Centers Llc, Bringing Physical Retail Chain to Delic Portfolio

Retrieved on:

Tuesday, June 8, 2021

Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Dissociative drugs, Sedatives, Chloroarenes, Nicotinic antagonists, Ketamine, WellPet, OTC Markets Group

VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the "Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").

Key Points:

VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the "Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").
Supported by clinical trials and peer reviewed studies, ketamine infusions have emerged as a promising treatment option for chronic diseases and pain disorders.
We are focused on making psychedelic wellness truly accessible, and this is a huge development in the realization of that vision."
DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Retrieved on:

Monday, June 7, 2021

Most recently, the FDA has granted priority review of maribavir for the treatment of post-transplant recipients with CMV infection in those R/R to prior anti-CMV treatment.

Key Points:

Most recently, the FDA has granted priority review of maribavir for the treatment of post-transplant recipients with CMV infection in those R/R to prior anti-CMV treatment.
Avery R. Randomized Phase 3 Open-Label Study of Maribavir vs Investigator-Assigned Therapy for Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: Subgroup Analyses of Efficacy by Organ.
Duarte R. Maribavir Versus Investigator-Assigned Therapy for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus Infection: Efficacy Data From a Randomized Phase 3 Open-Label Study.
Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients.